| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target of (±)-Decursinol is FtsZ (filamenting temperature-sensitive mutant Z), a protein essential for bacterial cell division. By inhibiting FtsZ polymerization, the compound prevents bacterial cell division. The compound also targets pathways involved in inflammation, oxidative stress, and neuroprotection. Additionally, it has vasodilatory and anti-platelet aggregation activities. These targets make it relevant for antibacterial, cardiovascular, and neuroprotective research.
|
|---|---|
| ln Vitro |
In vitro, (±)-Decursinol inhibits B. anthracis FtsZ polymerization with an IC50 of 102 μM. It demonstrates anti-inflammatory, anti-oxidative, and neuroprotective effects. The compound also shows vasodilatory and anti-platelet aggregation activities. These in vitro activities support its use in research on antibacterial agents, cardiovascular diseases, inflammation, oxidative stress, and neuroprotection.
|
| ln Vivo |
In vivo, (±)-Decursinol has potential therapeutic applications in the treatment of cardiovascular diseases such as hypertension and atherosclerosis, due to its vasodilatory and anti-platelet aggregation activities. Its anti-inflammatory, anti-oxidative, and neuroprotective effects suggest potential applications in inflammatory and neurodegenerative diseases. However, detailed in vivo efficacy data are limited. Further studies are needed to evaluate its therapeutic potential in animal models.
|
| Enzyme Assay |
In vitro enzyme assays for (±)-Decursinol involve measuring FtsZ polymerization inhibition. The compound is incubated with B. anthracis FtsZ at concentrations ranging from 0.1-1000 μM, and polymerization is measured spectrophotometrically or by light scattering. IC50 values are determined. Antioxidant activity is assessed using DPPH or ABTS assays. Anti-inflammatory activity is assessed by measuring cytokine production. Anti-platelet aggregation is assessed using platelet-rich plasma. All assays include appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for (±)-Decursinol are conducted using various cell lines depending on the application. For antibacterial studies, B. anthracis cultures are used. For cardiovascular studies, endothelial cells or smooth muscle cells are used. Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. Cell viability is assessed using MTT assays. Inflammatory cytokine production is measured by ELISA. Platelet aggregation is assessed using aggregometry. Experiments include vehicle controls and positive controls.
|
| Animal Protocol |
In vivo animal studies with (±)-Decursinol are limited, as the compound is primarily used as a research tool. Cardiovascular studies may be conducted in models of hypertension or atherosclerosis. Neuroprotection studies may be conducted in models of neurodegenerative diseases. Anti-inflammatory studies may be conducted in models of inflammation. The compound is administered via intraperitoneal or oral routes at doses ranging from 1-50 mg/kg. Each group consists of 6-10 animals with vehicle-treated controls.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (±)-Decursinol have not been extensively characterized. As a small, lipophilic coumarin derivative, it is expected to have good oral bioavailability and tissue distribution. The compound is from Angelica and likely undergoes hepatic metabolism through oxidation and conjugation, with elimination via biliary and renal excretion. Detailed PK parameters such as half-life, Cmax, and AUC require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicological data for (±)-Decursinol indicate that it is generally well-tolerated at concentrations used for research. As a natural product from Angelica, it is expected to have a reasonable safety profile. No significant toxicity has been reported. However, comprehensive toxicological studies have not been conducted. As with all research chemicals, appropriate safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
Coumarins belong to the coumarin class of compounds. It has been reported that coumarins are found in angelica gigas and custard apple (Phlojodicarpus villosus), and related data have been reported.
(±)-Decursinol is a potent FtsZ inhibitor that inhibits B. anthracis FtsZ polymerization with an IC50 of 102 μM. It exhibits anti-inflammatory, anti-oxidative, and neuroprotective effects and has vasodilatory and anti-platelet aggregation activities. The compound is from Angelica and has potential applications in antibacterial, cardiovascular, and neuroprotective research. Not approved for clinical therapeutic use; intended for research purposes. |
| Molecular Formula |
C₁₄H₁₄O₄
|
|---|---|
| Molecular Weight |
246.26
|
| Exact Mass |
246.089
|
| CAS # |
5993-18-0
|
| PubChem CID |
600671
|
| Appearance |
White to light yellow solid powder
|
| Melting Point |
181.5 °C
|
| LogP |
1.867
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C(CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)O)C
|
| InChi Key |
BGXFQDFSVDZUIW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H14O4/c1-14(2)12(15)6-9-5-8-3-4-13(16)17-10(8)7-11(9)18-14/h3-5,7,12,15H,6H2,1-2H3
|
| Chemical Name |
3-hydroxy-2,2-dimethyl-3,4-dihydropyrano[3,2-g]chromen-8-one
|
| Synonyms |
(±)Decursinol; (±) Decursinol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~406.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 0.27 mg/mL (1.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0607 mL | 20.3037 mL | 40.6075 mL | |
| 5 mM | 0.8121 mL | 4.0607 mL | 8.1215 mL | |
| 10 mM | 0.4061 mL | 2.0304 mL | 4.0607 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
